000 | 01727 a2200493 4500 | ||
---|---|---|---|
005 | 20250513212805.0 | ||
264 | 0 | _c20000727 | |
008 | 200007s 0 0 eng d | ||
022 | _a0021-9150 | ||
024 | 7 |
_a10.1016/s0021-9150(00)00379-8 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPauciullo, P | |
245 | 0 | 0 |
_aEfficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). _h[electronic resource] |
260 |
_bAtherosclerosis _cJun 2000 |
||
300 |
_a429-36 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aBezafibrate _xtherapeutic use |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 |
_aCholesterol, HDL _xblood |
650 | 0 | 4 |
_aCholesterol, LDL _xblood |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 |
_aFatty Acids, Monounsaturated _xtherapeutic use |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFluvastatin |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
650 | 0 | 4 |
_aHyperlipoproteinemia Type V _xblood |
650 | 0 | 4 |
_aHypolipidemic Agents _xtherapeutic use |
650 | 0 | 4 |
_aIndoles _xtherapeutic use |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aSafety |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTriglycerides _xblood |
700 | 1 | _aBorgnino, C | |
700 | 1 | _aPaoletti, R | |
700 | 1 | _aMariani, M | |
700 | 1 | _aMancini, M | |
773 | 0 |
_tAtherosclerosis _gvol. 150 _gno. 2 _gp. 429-36 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0021-9150(00)00379-8 _zAvailable from publisher's website |
999 |
_c10807532 _d10807532 |